Zacks: InspireMD, Inc. (NSPR) Given $15.00 Consensus Price Target by Brokerages

Shares of InspireMD, Inc. (NASDAQ:NSPR) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus target price of $15.00 for the company and are anticipating that the company will post ($2.50) earnings per share for the current quarter, according to Zacks. Zacks has also assigned InspireMD an industry rank of 88 out of 255 based on the ratings given to its competitors.

Separately, HC Wainwright reaffirmed a “buy” rating on shares of InspireMD in a research note on Wednesday, March 13th.

NASDAQ:NSPR opened at $6.39 on Friday. InspireMD has a 52 week low of $6.15 and a 52 week high of $82.00.

InspireMD (NASDAQ:NSPR) last posted its quarterly earnings data on Tuesday, February 19th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.82 million for the quarter.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on InspireMD (NSPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.